Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Oral Oncol ; 85: 40-43, 2018 10.
Article in English | MEDLINE | ID: mdl-30220318

ABSTRACT

OBJECTIVES: High institutional clinical trial recruitment and high hospital volume are reported to be independent indicators of better patient outcomes following cancer treatment. However, their relationship in head and neck cancers (HNC) remains less clear. METHODS: We aimed to assess the relationship between institutional clinical trial recruitment, hospital throughput of HNC cases, and survival of patients with advanced HNC treated with primary chemoradiotherapy at hospitals which recruited to the PET-NECK trial (2008-2012). The impact on outcome was assessed using Cox's proportional hazards regression analysis and multivariate analysis. RESULTS: HNC RCT recruitment positively correlated with hospital throughput (r = 0.57, p < 0.0001). Low-recruiters (1-5 patients) had a 107% increased risk of death when compared to high-recruiters (>5 patients) (HR = 2.07, p = 0.05). There was no significant impact of hospital throughput on overall or disease-specific HNC survival. Multivariate analysis identified p16 status, N-stage, smoking, and RCT recruitment volume as the only significant predictors of survival. There was a significant difference in chemotherapy regimen between low and high-recruiters (p = 0.003) where a higher proportion of patients (50%, n = 13) in low-recruiting compared to high-recruiting hospitals (29%, n = 92) received neoadjuvant chemotherapy. A higher proportion of these patients died at low-recruiting hospitals (46% versus 23%). DISCUSSION: A significant association exists between high recruitment and better OS for patients with HNC. However, no significance was found between hospital throughput and outcomes. The significance of individual centre differences in chemotherapy regimen needs further investigation. Future studies need a greater number of patient outcome events to support the trends found in this study.


Subject(s)
Clinical Trials as Topic , Head and Neck Neoplasms/mortality , Multicenter Studies as Topic , Patient Selection , Adult , Aged , Chemoradiotherapy , Clinical Trials as Topic/statistics & numerical data , England/epidemiology , Female , Head and Neck Neoplasms/therapy , Hospitals, High-Volume , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multicenter Studies as Topic/statistics & numerical data , Proportional Hazards Models
2.
N Engl J Med ; 374(15): 1444-54, 2016 Apr 14.
Article in English | MEDLINE | ID: mdl-27007578

ABSTRACT

BACKGROUND: The role of image-guided surveillance as compared with planned neck dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of debate. METHODS: In this prospective, randomized, controlled trial, we assessed the noninferiority of positron-emission tomography-computed tomography (PET-CT)-guided surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection performed only if PET-CT showed an incomplete or equivocal response) to planned neck dissection in patients with stage N2 or N3 disease. The primary end point was overall survival. RESULTS: From 2007 through 2012, we recruited 564 patients (282 patients in the planned-surgery group and 282 patients in the surveillance group) from 37 centers in the United Kingdom. Among these patients, 17% had nodal stage N2a disease and 61% had stage N2b disease. A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that stained positive for the p16 protein, an indicator that human papillomavirus had a role in the causation of the cancer. The median follow-up was 36 months. PET-CT-guided surveillance resulted in fewer neck dissections than did planned dissection surgery (54 vs. 221); rates of surgical complications were similar in the two groups (42% and 38%, respectively). The 2-year overall survival rate was 84.9% (95% confidence interval [CI], 80.7 to 89.1) in the surveillance group and 81.5% (95% CI, 76.9 to 86.3) in the planned-surgery group. The hazard ratio for death slightly favored PET-CT-guided surveillance and indicated noninferiority (upper boundary of the 95% CI for the hazard ratio, <1.50; P=0.004). There was no significant difference between the groups with respect to p16 expression. Quality of life was similar in the two groups. PET-CT-guided surveillance, as compared with neck dissection, resulted in savings of £1,492 (approximately $2,190 in U.S. dollars) per person over the duration of the trial. CONCLUSIONS: Survival was similar among patients who underwent PET-CT-guided surveillance and those who underwent planned neck dissection, but surveillance resulted in considerably fewer operations and it was more cost-effective. (Funded by the National Institute for Health Research Health Technology Assessment Programme and Cancer Research UK; PET-NECK Current Controlled Trials number, ISRCTN13735240.).


Subject(s)
Carcinoma, Squamous Cell/therapy , Head and Neck Neoplasms/therapy , Neck Dissection , Positron-Emission Tomography , Tomography, X-Ray Computed , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/surgery , Chemoradiotherapy , Female , Follow-Up Studies , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/surgery , Humans , Intention to Treat Analysis , Kaplan-Meier Estimate , Lymphatic Metastasis/diagnosis , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Prospective Studies , Quality of Life , Survival Rate
3.
J Clin Oncol ; 33(15): 1680-7, 2015 May 20.
Article in English | MEDLINE | ID: mdl-25897160

ABSTRACT

PURPOSE: Evidence supporting the clinical utility of predictive biomarkers of anthracycline activity is weak, with a recent meta-analysis failing to provide strong evidence for either HER2 or TOP2A. Having previously shown that duplication of chromosome 17 pericentromeric alpha satellite as measured with a centromere enumeration probe (CEP17) predicted sensitivity to anthracyclines, we report here an individual patient-level pooled analysis of data from five trials comparing anthracycline-based chemotherapy with CMF (cyclophosphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy for early breast cancer. PATIENTS AND METHODS: Fluorescent in situ hybridization for CEP17, HER2, and TOP2A was performed in three laboratories on samples from 3,846 of 4,864 eligible patients from five trials evaluating anthracycline-containing chemotherapy versus CMF. Methodologic differences did not affect HER2-to-CEP17 ratios but necessitated different definitions for CEP17 duplication: > 1.86 observed copies per cell for BR9601, NEAT, Belgian, and DBCG89D trials and > 2.25 for the MA.5 trial. RESULTS: Fluorescent in situ hybridization data were available in 89.3% (HER2), 83.9% (CEP17), and 80.6% (TOP2A) of 3,846 patient cases with available tissue. Both CEP17and TOP2A treatment-by-marker interactions remained significant in adjusted analyses for recurrence-free and overall survival, whereas HER2 did not. A combined CEP17 and TOP2A-adjusted model predicted anthracycline benefit across all five trials for both recurrence-free (hazard ratio, 0.64; 95% CI, 0.51 to 0.82; P = .001) and overall survival (hazard ratio, 0.66; 95% CI, 0.51 to 0.85; P = .005). CONCLUSION: This prospectively planned individual-patient pooled analysis of patient cases from five adjuvant trials confirms that patients whose tumors harbor either CEP17 duplication or TOP2A aberrations, but not HER2 amplification, benefit from adjuvant anthracycline chemotherapy.


Subject(s)
Anthracyclines/therapeutic use , Antigens, Neoplasm/genetics , Centromere/chemistry , Chromosomes, Human, Pair 17/genetics , DNA Topoisomerases, Type II/genetics , DNA-Binding Proteins/genetics , Fluorescent Dyes/chemistry , Neoplasms/drug therapy , Neoplasms/genetics , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor , Clinical Trials, Phase III as Topic , Cyclophosphamide/therapeutic use , Disease-Free Survival , Fluorouracil/therapeutic use , Genetic Markers , Humans , In Situ Hybridization, Fluorescence , Methotrexate/therapeutic use , Neoplasm Recurrence, Local , Poly-ADP-Ribose Binding Proteins , Prognosis , Proportional Hazards Models , Treatment Outcome
4.
J Clin Oncol ; 28(30): 4575-80, 2010 Oct 20.
Article in English | MEDLINE | ID: mdl-20837956

ABSTRACT

PURPOSE: Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer (CRC). PATIENTS AND METHODS: Patients who had undergone potentially curative surgery and completion of adjuvant therapy for stage II and III CRC were randomly assigned to receive rofecoxib (20 mg daily) or placebo. The primary end point was overall survival (OS). Where formalin-fixed paraffin-embedded tumor tissue samples were available, COX-2 expression was evaluated by immunohistochemistry and correlated with clinical outcome. RESULTS: Two thousand four hundred thirty-four patients were entered onto the study. The trial was terminated early because of the worldwide withdrawal of rofecoxib. At this point, 1,167 patients had received rofecoxib and 1,160 patients had received placebo for median treatment durations of 7.4 and 8.2 months, respectively. For the rofecoxib and placebo arms, median follow-up times were 4.84 and 4.85 years, with 241 and 246 deaths and 297 and 329 recurrences, respectively. No difference was demonstrated in OS (hazard ratio [HR] = 0.97; 95% CI, 0.81 to 1.16; P = .75) or recurrence (HR = 0.89; 95% CI, 0.76 to 1.04; P = .15) comparing the two groups. Tumor COX-2 expression by immunohistochemistry was assessed for 871 patients, but neither prognostic nor predictive effects were observed. CONCLUSION: In this study of abbreviated therapy in the adjuvant setting of CRC, rofecoxib did not improve OS or protect from recurrence in unselected patients. In addition, COX-2 expression did not correlate with prognosis overall or predict effectiveness of COX-2 inhibitors.


Subject(s)
Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/surgery , Cyclooxygenase 2 Inhibitors/therapeutic use , Lactones/therapeutic use , Sulfones/therapeutic use , Aged , Chemotherapy, Adjuvant , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Cyclooxygenase 2/analysis , Cyclooxygenase 2 Inhibitors/adverse effects , Disease-Free Survival , Double-Blind Method , Early Termination of Clinical Trials , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Lactones/adverse effects , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Proportional Hazards Models , Risk Assessment , Risk Factors , Safety-Based Drug Withdrawals , Sulfones/adverse effects , Time Factors , Treatment Outcome , United Kingdom
5.
Head Neck ; 31(12): 1600-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19455705

ABSTRACT

BACKGROUND: The aim of this study was to inform an evidence-based management policy for oral dysplastic lesions. METHODS: Systematic review was performed with meta-analysis. Studies reporting follow-up of patients with histologically confirmed oral dysplasia were included. Outcome measures included malignant transformation rate (MTR) and time to malignant transformation (TMT). Subgroup analysis was performed by histologic grade, clinical risk factors, and treatment modality. Heterogeneity was assessed. RESULTS: Fourteen nonrandomized studies, reporting on 992 patients, were included. There was considerable heterogeneity between studies: mean overall MTR = 12.1% (confidence interval: 8.1%, 17.9%) and mean TMT = 4.3 years. Histologic grade significantly affected mean MTR (p < .008). Lesions that were not excised demonstrated considerably higher MTR than those that were excised (p = .003). CONCLUSIONS: Oral dysplasia showed a significant rate of transformation to cancer, which was related to grade and was decreased significantly but not eliminated by excision. This suggested the need for excision and continued surveillance.


Subject(s)
Cell Transformation, Neoplastic/pathology , Mouth Neoplasms/pathology , Mouth/pathology , Precancerous Conditions/pathology , Precancerous Conditions/surgery , Clinical Trials as Topic , Evidence-Based Medicine , Female , Follow-Up Studies , Humans , Hyperplasia/pathology , Incidence , Male , Mouth Diseases/pathology , Mouth Diseases/therapy , Mouth Neoplasms/epidemiology , Mouth Neoplasms/surgery , Mouth Neoplasms/therapy , Precancerous Conditions/therapy , Risk Assessment
6.
N Engl J Med ; 357(4): 360-9, 2007 Jul 26.
Article in English | MEDLINE | ID: mdl-17652651

ABSTRACT

BACKGROUND: Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS: All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, started after potentially curative tumor resection and chemotherapy or radiotherapy as indicated. The trial was terminated prematurely owing to worldwide withdrawal of rofecoxib. To examine possible persistent risks, we examined cardiovascular thrombotic events reported up to 24 months after the trial was closed. RESULTS: The median duration of active treatment was 7.4 months. The 1167 patients receiving rofecoxib and the 1160 patients receiving placebo were well matched, with a median follow-up period of 33.0 months (interquartile range, 27.6 to 40.1) and 33.4 months (27.7 to 40.4), respectively. Of the 23 confirmed cardiovascular thrombotic events, 16 occurred in the rofecoxib group during or within 14 days after the treatment period, with an estimated relative risk of 2.66 (from the Cox proportional-hazards model; 95% confidence interval [CI], 1.03 to 6.86; P=0.04). Analysis of the Antiplatelet Trialists' Collaboration end point (the combined incidence of death from cardiovascular, hemorrhagic, and unknown causes; of nonfatal myocardial infarction; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative risk of 1.60 (95% CI, 0.57 to 4.51; P=0.37). Fourteen more cardiovascular thrombotic events, six in the rofecoxib group, were reported within the 2 years after trial closure, with an overall unadjusted relative risk of 1.50 (95% CI, 0.76 to 2.94; P=0.24). Four patients in the rofecoxib group and two in the placebo group died from thrombotic causes during or within 14 days after the treatment period, and during the follow-up period, one patient in the rofecoxib group and five patients in the placebo group died from cardiovascular causes. CONCLUSIONS: Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration. (Current Controlled Trials number, ISRCTN98278138 [controlled-trials.com].).


Subject(s)
Adenoma/prevention & control , Cardiovascular Diseases/chemically induced , Colorectal Neoplasms/prevention & control , Cyclooxygenase 2 Inhibitors/adverse effects , Lactones/adverse effects , Neoplasm Recurrence, Local/prevention & control , Sulfones/adverse effects , Adenoma/surgery , Aged , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/mortality , Chemotherapy, Adjuvant , Colorectal Neoplasms/surgery , Cyclooxygenase 2 Inhibitors/therapeutic use , Female , Follow-Up Studies , Humans , Incidence , Lactones/therapeutic use , Male , Middle Aged , Risk , Sulfones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...